Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Stock Rated “Buy” by Sell-Side Brokerages

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have earned an average rating of “Buy” from the eleven analysts that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $11.50.

A number of research firms have commented on CATX. Bank of America decreased their target price on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating on the stock in a research report on Friday, August 14th. Piper Sandler cut their price target on Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research note on Tuesday, August 11th. William Blair initiated coverage on Perspective Therapeutics in a research note on Friday, September 18th. They set an “outperform” rating for the company. BMO Capital Markets set a $11.00 price objective on shares of Perspective Therapeutics and gave the stock an “outperform” rating in a research report on Tuesday, August 18th. Finally, BTIG Research reissued a “buy” rating and issued a $14.00 price objective on shares of Perspective Therapeutics in a research note on Wednesday, October 7th.

Hedge Funds Weigh In On Perspective Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wealth Effects LLC grew its stake in shares of Perspective Therapeutics by 32.0% in the first quarter. Wealth Effects LLC now owns 33,000 shares of the company’s stock valued at $138,000 after buying an additional 8,000 shares in the last quarter. Abel Hall LLC purchased a new stake in shares of Perspective Therapeutics during the first quarter valued at approximately $49,000. Taylor & Morgan Wealth Management LLC lifted its position in shares of Perspective Therapeutics by 30.3% during the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after purchasing an additional 20,000 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Perspective Therapeutics in the fourth quarter valued at $84,000. Finally, Quantinno Capital Management LP acquired a new stake in Perspective Therapeutics during the 1st quarter valued at $273,000. Institutional investors and hedge funds own 54.66% of the company’s stock.

Perspective Therapeutics Trading Down 9.9%

CATX stock opened at $2.27 on Wednesday. The firm has a 50 day moving average of $2.92 and a 200-day moving average of $3.37. Perspective Therapeutics has a 12-month low of $1.96 and a 12-month high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its quarterly earnings results on Monday, August 10th. The company reported ($0.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.09 million. Perspective Therapeutics had a negative return on equity of 41.92% and a negative net margin of 28,467.97%. Sell-side analysts forecast that Perspective Therapeutics will post -0.98 earnings per share for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc is a clinical-stage radiopharmaceutical biotechnology company developing precision-targeted alpha therapies for cancer. The company’s approach combines tumor-targeting molecules with radioactive isotopes to deliver highly focused radiation to cancer cells while limiting exposure to surrounding healthy tissue.

Perspective’s proprietary VMT platform is designed to support both diagnostic imaging and therapeutic applications. Its lead programs include VMT-α-NET, an investigational therapy targeting somatostatin receptor 2 for patients with neuroendocrine tumors, and VMT01, an investigational program targeting melanocortin 1 receptor-expressing cancers, including certain metastatic melanomas.